Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
NCT ID: NCT00039013
Last Updated: 2015-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
336 participants
INTERVENTIONAL
2002-03-31
2003-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus
NCT00035984
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea
NCT00039026
A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
NCT03985293
Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
NCT00817778
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
NCT00995787
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AC2993 5 mcg (0.02 mL)
Placebo, then AC2993 5 mcg, then AC2993 5 mcg
AC2993
Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
AC2993 10mcg (0.04 mL)
Placebo, then AC2993 5 mcg, then AC2993 10 mcg
AC2993
Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Placebo 0.02 mL
Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
Placebo
Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Placebo 0.04 mL
Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
Placebo
Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AC2993
Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
AC2993
Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Placebo
Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Placebo
Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treated with metformin within a defined dose range for at least 3 months prior to screening
* BMI= 27-45 kg/m2
* HbA1c value between 7.5% and 11%
Exclusion Criteria
* Patients treated previously with AC2993
* Patients presently treated with insulin
16 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pinnacle Research Group
Anniston, Alabama, United States
Parkway Medical Center
Birmingham, Alabama, United States
Alabama Clinical Therapeutics
Birmingham, Alabama, United States
Eclectic Family Care
Eclectic, Alabama, United States
Winston Physician Services
Haleyville, Alabama, United States
Simon Williamson Clinic
Hueytown, Alabama, United States
Extended Arm Physicians/ Southern Drug
Montgomery, Alabama, United States
Southern Drug Research Network
Tallassee, Alabama, United States
Clinic of Physicians and Surgeons, Ltd.
Mesa, Arizona, United States
ANA Ventures, LLC
Mesa, Arizona, United States
Lovelace Scientific Resources-Phoenix
Phoenix, Arizona, United States
Physicians at the Peak
Phoenix, Arizona, United States
Advanced Clinical Therapeutics
Tucson, Arizona, United States
CAVHS
Little Rock, Arkansas, United States
Physicians Group Research Clinic, LLC
Little Rock, Arkansas, United States
Advanced Clinical Research Institute
Anaheim, California, United States
Mitchell Research Group, Inc.
Bakersfield, California, United States
William Zigrang, M.D.
Burlingame, California, United States
International Clinical Research Network
Chula Vista, California, United States
Arrowhead Regional Medical Center
Colton, California, United States
Valley Research
Fresno, California, United States
Elke Jost-Vu, M.D.
Rancho Mirage, California, United States
Comprehensive Diabetes-Endocrine Medical Associates
Redwood City, California, United States
nTouch
San Diego, California, United States
Radiant Research-San Diego
San Diego, California, United States
Veterans Medical Research Foundation
San Diego, California, United States
Diabetes Research Institute of Mills Peninsula
San Mateo, California, United States
Advanced Clinical Research Institute
Santa Ana, California, United States
West Coast Clinical Trials
Signal Hill, California, United States
Protocare Trials at Sharp Mission Park
Vista, California, United States
Diablo Clinical Research
Walnut Creek, California, United States
Medstar Clinical Research
Washington D.C., District of Columbia, United States
George Washington University
Washington D.C., District of Columbia, United States
Internal Medical Associates
Fort Myers, Florida, United States
Clin Sci International
Gainesville, Florida, United States
University of FL
Gainesville, Florida, United States
Jupiter Research Institute
Jupiter, Florida, United States
Baptist Diabetes Associates
Miami, Florida, United States
Tampa Medical Group
Tampa, Florida, United States
Metabolic Research Institute, Inc.
West Palm Beach, Florida, United States
Radiant Research
West Palm Beach, Florida, United States
nTouch Research Corporation
Decatur, Georgia, United States
East-West Medical Research Institute
Honolulu, Hawaii, United States
St. Luke's Family Health
Meridian, Idaho, United States
University Primary Care Center at Belvidere
Belvidere, Illinois, United States
Northwestern Memorial Physicians Group
Chicago, Illinois, United States
Illinois Center for Clinical Trials
Chicago, Illinois, United States
Lake Forest Internal Medicine
Libertyville, Illinois, United States
Winchester Research Group
Libertyville, Illinois, United States
Medical Group of Fort Wayne
Fort Wayne, Indiana, United States
American Health Network
Indianapolis, Indiana, United States
Center for Metabolic and Hormonal Disorders
Indianapolis, Indiana, United States
nTouch Research-South Bend
South Bend, Indiana, United States
Kentucky Diabetes Center
Lexington, Kentucky, United States
University of Kentucky Metabolic Research Group
Lexington, Kentucky, United States
MedResearch, Inc.
Louisville, Kentucky, United States
Drug Research Services
Metairie, Louisiana, United States
New Orleans Institute of Clinical Investigation
New Orleans, Louisiana, United States
Ochsner Clinic
New Orleans, Louisiana, United States
St. Agnes Health Care
Baltimore, Maryland, United States
Doctors Research Associates of Maryland
Lanham, Maryland, United States
Grunberger Diabetes Medical Center
Bloomfield Hills, Michigan, United States
Henry Ford Health System
Detroit, Michigan, United States
Grand Rapids Associated Interns
Grand Rapids, Michigan, United States
University of Mississippi Medical Center
Jackson, Mississippi, United States
Diabetes and Endocrinology Specialists
Chesterfield, Missouri, United States
Midwest Pharmaceutical Research
City of Saint Peters, Missouri, United States
Mid Missouri Research Specialists, Inc.
Rolla, Missouri, United States
Radiant Research-St. Louis
St Louis, Missouri, United States
Mercury Street Medical
Butte, Montana, United States
Lovelace Scientific Resources-Las Vegas
Las Vegas, Nevada, United States
HIS Clinical Research
Jersey City, New Jersey, United States
Radiant Research-Moorestown
Moorestown, New Jersey, United States
New Jersey Physicians
Passaic, New Jersey, United States
Lovelace Scientific Resources
Albuquerque, New Mexico, United States
Medical Network Services, P.C.
Brooklyn, New York, United States
St. Lukes Roosevelt Hospital
New York, New York, United States
Naomi Berrie Diabetes Center at Columbia University
New York, New York, United States
Heights Medical Care
New York, New York, United States
Rochester Clinical Research
Rochester, New York, United States
DOCS at Beth Israel Medical Center
Yonkers, New York, United States
Metrolina Medical Research
Charlotte, North Carolina, United States
Charlotte Clinical Research
Charlotte, North Carolina, United States
UNC Diabetes Care Center
Durham, North Carolina, United States
Unifour Medical Research
Hickory, North Carolina, United States
New Hanover Medical Research Associates
Wilmington, North Carolina, United States
Piedmont Medical Research
Winston-Salem, North Carolina, United States
Rapid Medical Research
Cleveland, Ohio, United States
Ohio State University-Division of Endocrinology
Columbus, Ohio, United States
Radiant Research-Columbus
Columbus, Ohio, United States
University Mednet
Mentor, Ohio, United States
COR Clinical Research
Oklahoma City, Oklahoma, United States
nTouch Research Corporation-Oklahoma City
Oklahoma City, Oklahoma, United States
Utica Park Clinic
Tulsa, Oklahoma, United States
Medford Medical Clinic
Medford, Oregon, United States
Legacy Clinical Research
Portland, Oregon, United States
Radiant Research
Portland, Oregon, United States
Physicians for Clinical Research
Camp Hill, Pennsylvania, United States
Thomas Jefferson University Diabetes Research Center
Philadelphia, Pennsylvania, United States
Philadelphia Health Associates
Philadelphia, Pennsylvania, United States
Tipton Medical and Diagnostic Center
Tipton, Pennsylvania, United States
Safe Harbor Clinical Research
East Providence, Rhode Island, United States
Radiant Research-Charleston
Charleston, South Carolina, United States
CNS Clinical Trials
Chester, South Carolina, United States
Coastal Carolina Research Center
Mt. Pleasant, South Carolina, United States
Integrity Clinical Research
Jackson, Tennessee, United States
Harmony Clinical Research
Johnson City, Tennessee, United States
Holston Medical Group
Kingsport, Tennessee, United States
Endocrine Consultants of ET
Knoxville, Tennessee, United States
Central Texas Clinical Research
Austin, Texas, United States
Rafael Canadas M.D., P.A.
Dallas, Texas, United States
Texas Tech University Health Sciences-Internal Medicine
El Paso, Texas, United States
Internal Medicine Associates
El Paso, Texas, United States
North Texas Clinical Research
Irving, Texas, United States
Dr. Humberto Bruschetta
Kingsville, Texas, United States
South Texas Applied Research
McAllen, Texas, United States
University of Texas Health Sciences Center-Texas Diabetes Institute
San Antonio, Texas, United States
Diabetes and Glandular Disease Clinic
San Antonio, Texas, United States
SAM Clinical Research Center
San Antonio, Texas, United States
Salt Lake Research
Salt Lake City, Utah, United States
Evergreen Diabetes & Endocrinology
Kirkland, Washington, United States
West Olympia Internal Medicine
Olympia, Washington, United States
Rainier Clinical Research Center
Renton, Washington, United States
Northside Internal Medicine
Spokane, Washington, United States
Rockwood Clinic
Spokane, Washington, United States
Julia M. Hutchinson, M.D.
Spokane, Washington, United States
Wenatchee Valley Clinic
Wenatchee, Washington, United States
Hyperion Clinical Research
Charleston, West Virginia, United States
CAMC Clinical Trials Center
Charleston, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005 May;28(5):1092-100. doi: 10.2337/diacare.28.5.1092.
Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006 Jul;8(4):419-28. doi: 10.1111/j.1463-1326.2006.00589.x.
Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012 Jul;124(4):21-32. doi: 10.3810/pgm.2012.07.2567.
Fineman MS, Mace KF, Diamant M, Darsow T, Cirincione BB, Booker Porter TK, Kinninger LA, Trautmann ME. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012 Jun;14(6):546-54. doi: 10.1111/j.1463-1326.2012.01561.x. Epub 2012 Feb 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2993-112
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.